P/E ratio for Axon Enterprise (AXON)
P/E ratio as of April 2024 (TTM): 221
According to Axon Enterprise 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 221.394. At the end of 2022 the company had a P/E ratio of 80.2.
P/E ratio history for Axon Enterprise from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 80.2 | -147.48% |
| 2021 | -169 | -94.49% |
| 2020 | < -1000 | -141.8% |
| 2019 | > 1000 | 8777.35% |
| 2018 | 82.5 | -68.85% |
| 2017 | 265 | 249.83% |
| 2016 | 75.8 | 66.48% |
| 2015 | 45.5 | -36.42% |
| 2014 | 71.6 | 71.26% |
| 2013 | 41.8 | 30.88% |
| 2012 | 31.9 | -174.83% |
| 2011 | -42.7 | -36.45% |
| 2010 | -67.1 | |
| 2008 | 88.0 | 46.77% |
| 2007 | 60.0 | -155.15% |
| 2006 | -109 | -146.86% |
| 2005 | 232 | 149.23% |
| 2004 | 93.1 | 54.83% |
| 2003 | 60.1 | 4.13% |
| 2002 | 57.7 | -7.62% |
| 2001 | 62.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 XBiotech XBIT | -10.0 | -104.52% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -0.3855 | -100.17% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Exelixis EXEL | 80.1 | -63.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.